Drugs.com Clinical Trial ResultsOriginal article
Novo Nordisk's Denecimig (Mim8) Demonstrated Positive Results in Long Term Safety and Efficacy in Phase 3 Hemophilia A FRONTIER Extension Study
Phase 3positiveDenecimigPositive
AI Analysis
Summary
Novo Nordisk announced positive long-term safety and efficacy results from the Phase 3 FRONTIER4 extension study of denecimig (Mim8) for hemophilia A. The data demonstrates continued benefit in the investigational gene therapy candidate.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Demonstrated positive results in long-term safety and efficacy in Phase 3 FRONTIER4 extension study
Importance:7/10
Sentiment:
0.75
hemophilia Agene therapyphase 3extension studylong-term safety
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on July 11, 2026 3:07 AM